secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001493152-25-016001
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo posts Q4 net loss $2.1M; starts Phase 1 IV selonabant; proposes reverse split for going private
--------------------------------------------------------------------------------

- Q4 FY2025 net loss of $2.1M ($0.05/shr) vs $1.3M ($0.05/shr) prior year; full-year net loss $8.5M ($0.25/shr) vs $8.2M ($0.32/shr).
- First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric acute cannabis toxicity on September 25, 2025.
- Received year-2 NIDA/NIH grant of $994,300 to support the SAD study of IV selonabant.
- Board approved reverse stock split to reduce record holders below 300 as part of proposed going-private transaction; special meeting pending.
- Cash and cash equivalents $11.6M at June 30, 2025; additional $3M available under loan agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/0001493152-25-016001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225016001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer